Johnson & Johnson-backed HistoSonics, a developer of sonic beams that attack tumours, is pursuing a sale after fielding takeover bids from several suitors, said people familiar with the matter.

Despite cuts to earnings or multiples, all brokerages retained a positive view. Citi, Nomura, and JPMorgan reiterated their ...